Integra LifeSciences
IART
264 hedge funds and large institutions have $3.39B invested in Integra LifeSciences in 2020 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 91 increasing their positions, 95 reducing their positions, and 30 closing their positions.
23% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 30
6% more capital invested
Capital invested by funds: $3.2B → $3.39B (+$191M)
2% more funds holding
Funds holding: 258 → 264 (+6)
0.22% more ownership
Funds ownership: 84.92% → 85.14% (+0.22%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 95
52% less call options, than puts
Call options by funds: $1.74M | Put options by funds: $3.59M
Top Buyers
| 1 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$29.6M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$28.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$24.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.4M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.3M |
Top Sellers
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$28.8M |
| 2 |
Goldman Sachs
New York
|
-$15.9M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$15.4M |
| 4 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$9.98M |
| 5 |
Jennison Associates
New York
|
-$9.69M |
IART Hedge Fund Activity: Q2 2020 in Review
264 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2020, worth a combined $3.39B — up 6% from $3.2B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new IART positions and 30 closed out — a net gain of 7 holders — while 91 added to existing stakes and 95 trimmed.
The largest buyer was Eaton Vance Management, adding an estimated $29.6M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $28.8M.
- 264 institutional investors held Integra LifeSciences (IART) as of Q2 2020, up from 258 in Q1 2020.
- Funds reported $3.39B of Integra LifeSciences stock for Q2 2020, up 6% quarter-over-quarter.
- 37 funds opened new Integra LifeSciences positions in Q2 2020 and 30 closed out, a net change of +7 holders.
- The largest Integra LifeSciences buyer in Q2 2020 was Eaton Vance Management, an estimated $29.6M added.
- The largest Integra LifeSciences seller in Q2 2020 was ArrowMark Colorado Holdings, an estimated $28.8M sold.
Based on aggregated 13F filings for Q2 2020.